Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for CLL Patients

NCT04178317 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04178317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04178317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for CLL Patients
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
April 2, 2020
Completion date
August 18, 2025
Enrollment
14 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, chronic lymphocytic leukemia (cll)